Navigation Links
Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
Date:12/4/2007

REDWOOD CITY, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company focused on the development of improved protein drugs, announced today the license of its proprietary dengue virus antigen technology to sanofi pasteur, the vaccines division of the sanofi-aventis Group.

Under the terms of the agreement, Maxygen will transfer to sanofi pasteur a portfolio of preclinical dengue antigens for development and worldwide commercialization of a second generation vaccine. In addition to royalties, total event payments to Maxygen, including an upfront fee, could total $24.5 million.

The dengue virus is a mosquito-borne pathogen that infects over 50 million people each year, causing 500,000 hospitalizations for Dengue Hemorrhagic Fever/ Dengue Shock Syndrome, according to The World Health Organization (WHO). Without proper treatment, Dengue Shock Syndrome can be fatal.(1) WHO estimates that more than 20,000 people worldwide, mainly children, die each year from infection with the virus. While the majority of deaths occur in tropical and subtropical regions, the virus is spreading to new regions of the world, including Northern Australia, the Middle East, Central America, and the southern part of the United States. WHO estimates that 40 percent of the world's population is currently at risk of dengue infection.(2)

To date, efforts to develop a dengue vaccine have been challenged by the existence of four different serotypes of dengue virus, all of which are responsible for the severe form of the disease called Dengue Hemorrhagic Fever. To overcome this challenge, Maxygen used its proprietary MolecularBreeding(TM) directed molecular evolution platform. Segments of DNA fro
'/>"/>

SOURCE Maxygen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Maxygen Announces Hold on MAXY-alpha Development Program
2. Maxygen Third Quarter 2007 Financial Results Conference Call Notice
3. Maxygen Announces Upcoming Webcasts at Investor Conferences
4. Maxygen Reports Third Quarter 2007 Financial Results
5. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
6. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
7. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
8. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
9. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
10. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
11. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... international research team including DESY scientists has observed tiny ... team reports in the journal Science that ... inside the nanodroplets. It is the first time that ... larger samples of what is known as superfluid helium, ... our best expectations," says Andrey Vilesov of the University ...
(Date:8/21/2014)... COLD SPRING, N.Y. , Aug. 21, 2014 ... today the launch of their Nutraceutical "TELO-20 for ... first and only Telomere-lengthening supplement in the world ... the ends of every chromosome in the body. ... the world,s leading experts in Telomere Science and ...
(Date:8/21/2014)... 2014 OTC Markets Group Inc. ... biotechnology company, on its approval to list on ... OTCQX®, the best marketplace for established U.S. and ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... of its growth strategy and achievement of this ...
(Date:8/21/2014)... Bulgaria (PRWEB) August 21, 2014 ... released today by Ontotext . Now the ... semantic analysis of structured and unstructured data is available ... the cost of enterprise technology. Organizations that do not ... for data management can use S4 since there is ...
Breaking Biology Technology:Scientists observe quantum vortices in cold helium droplets 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4
... , BETHESDA, Md., Sept. 21 ... company developing novel, proprietary antibodies for the treatment of cancer, ... a phase 1 dose-escalation clinical study for BiTE antibody MT110, ... tumors. The interim data(1) were presented at the Multidisciplinary ...
... , , , ... 21 Volcano Corporation (Nasdaq: VOLC ), a leader ... and treatment of coronary and peripheral artery disease, announced today its ... Francisco, CA from September 21-25. Volcano programming for TCT includes a ...
... ST. PAUL, Minn., Sept. 21 Brennen Medical, LLC, ... device to Davol Inc., a subsidiary of C.R. Bard, Inc. ... of the hernia products business of Brennen Medical, LLC. This ... in soft tissue repair including hernia and abdominal wall reconstruction. , ...
Cached Biology Technology:Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors 2Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors 3Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors 4Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 2Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 3Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 4Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 5Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 6Brennen Medical Announces Sale of XenMatrix(R) 2
(Date:8/21/2014)... has successfully replicated one of the crucial steps in ... sunlight which could manufacture hydrogen as a fuel. , ... an exciting prospect to use them to create hydrogen, ... Hingorani, from the ARC Centre of Excellence for Translational ... Hydrogen offers potential as a zero-carbon replacement for petroleum ...
(Date:8/21/2014)... itself resulting in severe abdominal pain, vomiting and systemic ... are diagnosed with the disease resulting in 1000 deaths. ... to intravenous fluid and nutritional support. , Dr ... led the research, said "The major causes of pancreatitis ... alcohol intake combined with a high fat diet. In ...
(Date:8/20/2014)... a study of 158 pregnant teenagers in Rochester, NY, ... intentional consumption of ice, cornstarch, vacuum dust, baby powder ... Cornell study. , Moreover, such teens had significantly lower ... eat nonfood substances. , Pregnant teens, regardless of pica, ... lead to iron deficiency and anemia. Low iron in ...
Breaking Biology News(10 mins):Water and sunlight the formula for sustainable fuel 2Insulin offers new hope for the treatment of acute pancreatitis 2Pica in pregnant teens linked to low iron 2
... the behaviors of individual cells and the functions and ... the complex interactions of cell clusters have not been ... Emergent Behaviors of Integrated Cellular Systems (EBICS) Center to ... the University of Illinois at Urbana-Champaign, and the Georgia ...
... From how massive humpbacks glide through the sea with ease ... Harvard have excavated the equations behind a variety of complex ... Michael Brenner, working closely with a team of Harvard evolutionary ... most famous icon of evolution: the beaks of Darwin,s finches. ...
... industrialized countries have easy access to healthy food and nutritional ... because new research from Tel Aviv University suggests that magnesium, ... even more critical than previously thought for the neurons of ... MIT, the research started as a part of a post-doctoral ...
Cached Biology News:$25M NSF center established to investigate the creation of biological machines 2$25M NSF center established to investigate the creation of biological machines 3$25M NSF center established to investigate the creation of biological machines 4Simple math explains dramatic beak shape variation in Darwin's finches 2Simple math explains dramatic beak shape variation in Darwin's finches 3Remember magnesium if you want to remember 2
Mouse Activin RIB/ALK-4 MAb (Clone 207304)...
Normal human serum, single donor...
... SYBR Green, TaqMan, LNA spiked TaqMan, MethyLight, ... specific primers are designed by avoiding cross ... results. Primer efficiency is enhanced by avoiding ... the Mfold server. Beacon Designer can be ...
Agar, 5 lb. Bacteriological.Moisture: < 10%, ash: < 6.5%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: